UK Pharmacovigilance Requirements Following the End of the Brexit Transition Period
The United Kingdom (UK) left the European Union (EU) on 31st January 2020. The transition period is due to end on 1st January 2021. After this point, the UK will no longer be associated with the European Medicines Agency (EMA). Marketing authorization holders (MAHs) of products registered in the UK will need to follow the guidance of the Medicines and Healthcare products Regulatory Agency (MHRA), which is the local competent authority.
Download our recent whitepaper which introduces you to the most important UK pharmacovigilance requirements following the end of the Brexit transition period.